Multaq is a drug used to prevent and treat atrial fibrillation, a heart rhythm disorder. It is manufactured by Sanofi-Aventis, a French pharmaceutical company. Multaq was approved by the United States Food and Drug Administration (FDA) in 2009.
Multaq is a member of a class of drugs called antiarrhythmics. It works by blocking the action of certain chemicals in the heart that can cause atrial fibrillation. By blocking these chemicals, Multaq helps to restore the heart's normal rhythm.
Multaq is taken orally, typically two times per day. It can be taken with or without food. The most common side effects of Multaq include diarrhea, nausea, and vomiting. Less common side effects include chest pain, palpitations, and shortness of breath.
Multaq is contraindicated in people with severe heart failure or severe liver disease. It should also not be used in people who are taking certain other medications, including ketoconazole, erythromycin, itraconazole, and clarithromycin.
In clinical trials, Multaq was found to be effective in preventing atrial fibrillation from returning. It also appeared to be safe and well tolerated.
